Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous guselkumab induction therapy in moderately to severely active ulcerative colitis
2023-504719-34-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Guselkumab induction with Placebo (2 arms). Primary endpoint: Clinical remission. Planned start Feb 2023; status: authorised.
02
Drugs
guselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-504719-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504719-34-00.